CSIMarket Company Name, Ticker, Industry, else..
 
Gri Bio Inc   (NASDAQ: GRI)
Other Ticker:  
 
 
Price: $1.5000 $0.05 3.448%
Day's High: $1.51 Week Perf: -3.23 %
Day's Low: $ 1.40 30 Day Perf: 12.78 %
Volume (M): 121 52 Wk High: $ 59.33
Volume (M$): $ 181 52 Wk Avg: $11.10
Open: $1.45 52 Wk Low: $1.10



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Gri Bio Inc
Gri Bio Inc is a biotechnology company that specializes in the research, development, and production of innovative biologic therapies and products. They aim to provide effective and safe solutions for various diseases and medical conditions. Gri Bio Inc utilizes advanced technologies and scientific expertise to develop treatments that address unmet medical needs. They have a strong focus on improving patient outcomes and advancing the field of biotechnology. Overall, Gri Bio Inc is dedicated to improving the quality of life for individuals through their innovative biologic therapies.


   Company Address: 2223 Avenida de la Playa La Jolla 92037 CA
   Company Phone Number: 400-1170   Stock Exchange / Ticker: NASDAQ GRI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.22%    
BMY        1.35% 
REGN        3.25% 
TEVA   -5.68%    
VRTX   -0.16%    
VTRS   -1.34%    
• View Complete Report
   



Stocks on the Move

Gri Bio Inc Outperforms the Market with 3.35% Performance, Despite Cumulative Net Loss

Published Thu, Jul 4 2024 12:15 PM UTC

Gri Bio Inc, a biotechnology company focusing on Natural Killer T (NKT) cell modulators, has recently displayed promising performance despite facing certain challenges. This article aims to analyze the events surrounding Gri Bio Inc and its market performance, as well as discuss the company s net loss and return on assets in comparison to other healthcare sector companies.Gr...
Gri Bio Inc

Gri Bio Inc Surprises Stock Market with Positive Gain in Q1 2024 Report

Gri Bio Inc, a smaller entity in the Major Pharmaceutical Preparations sector, has recently reported its earnings for the first quarter of 2024. The company revealed an operating deficit of $-1.895 million, which represents an improvement from the previous year's first quarter numbers when the deficit was at $-2.349 million. While this deficit may be concerning, it is important to understand the overall state of Gri Bio Inc and its future prospects.
As an emerging growth entity, Gri Bio Inc is in the process of developing its business strategy and navigating the challenges that come with it. Operating economically is crucial for smaller entities like Gri Bio Inc, as it allows them to reach the next phase of growth and establish themselves as important players in the industry.
Gri Bio Inc

Struggling Gri Bio Inc Faces Challenges Amidst Widening Shortfalls and Dwindling Revenues: A Closer Look at Fourth Quarter 2023 Results



In the wake of Gri Bio Inc's fourth-quarter financial results, the company finds itself facing significant challenges as it grapples with widening shortfalls and dwindling revenues. The latest figures shed light on the extent of the company's struggles, making it a tough period for investors and stakeholders.
Financial Results Analysis:
Shifting our focus towards the fourth quarter of 2023, Gri Bio Inc reported a considerable increase in its shortfall per share, reaching $-0.73. This represents a substantial decline from the $-0.12 per share recorded during the same quarter a year ago. Furthermore, the preceding quarter saw a shortfall of $-0.52 per share.
Gri Bio Inc

Gri Bio Inc's Fiscal Q3 2023 Losses Exceed Previous Year's Figures, Yet Redemption Lies in Improved Earnings per Share2.

The stock market is a dynamic and ever-changing environment that offers immense opportunities for investors. One company that has caught the attention of investors is Gri Bio Inc. Despite facing some challenges in the fiscal third quarter of 2023, the company has shown significant improvements in its earnings per share (EPS) compared to the preceding reporting season.
In the fiscal third quarter of 2023, Gri Bio Inc experienced widened losses of $-0.52 per share, in contrast to $-0.09 per share a year ago. However, the company's EPS improved from $-2.79 per share in the previous reporting season, which is a positive sign for investors. This improvement indicates that the company has managed to address some of the issues that were impacting its profitability.
Gri Bio Inc

GRI Bio Inc Demonstrates Enhanced Company Behavior, Drives Strong Earnings in Second Quarter of 2023: A Closer Look at GRI's Progress


Introduction
In the competitive landscape of the Major Pharmaceutical Preparations sector, Gri Bio Inc has emerged as an intriguing contender, albeit lesser known compared to industry leaders. Despite facing an operating loss of $-5.934 million during the second quarter of 2023, the company's shareholders remain optimistic, anticipating a potential business model evolution in the near future. Gri Bio Inc's recent operational behavior may have raised concerns among some investors, but the company's quest for different corporate policies signals its commitment to ensuring steady business growth. Let us delve deeper into how these recent financial results have impacted Gri Bio Inc and why shareholders believe in the company's potential.
Challenges in the Expanding Stage
During the expanding stage, Gri Bio Inc experienced shortfalls amounting to $-6.746 million for the second quarter of 2023, compared to $-1.773 million in the same period of the previous year (Q2 2022). Such setbacks could dampen investor sentiment, but it is crucial to understand that this is a normal part of the growth process. The expenses incurred during this stage are often substantial due to increased investment in research and development, infrastructure, and marketing initiatives. Gri Bio Inc's ability to navigate these challenges demonstrates its resilience and determination to succeed in a competitive market.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com